Platform
The Opportunity for a novel expression system
FlyPharma is pioneering a new biomanufacturing platform that overcomes the cost and scalability constraints of current methods.
- Biologic proteins require sterile cell culture bioreactors
- Synthetic carotenoids rely on petrochemical processes
- Natural carotenoids remain expensive and difficult to scale
FlyPharma replaces these production routes with a genetically engineered insect expression platform.
Where the Advantage Lives
FlyPharma’s Platform advantage is structural.
It sits across three interlocking layers:
Genetics
Proprietary, performance-linked strains designed for expression at scale
Automation
Fully integrated production systems that deliver consistency and throughput
Know-How
Operational learning accumulated through real production, not simulations
Designed to be industrially scalable.
A New Expression System for Biologics
The FlyPharma Platform integrates:
- Exclusive GM strain rights
- Coupled genetics and automation systems
- Proprietary insect-scale process engineering
- Data-driven yield optimisation
The result is a step-change in production economics.
How the Platform Works
FlyPharma’s platform is designed as an industrial system, not a laboratory process.
1.
Genetically enabled BSF strains act as in vivo expression hosts
2.
Automated rearing systems ensure controlled, high-density production
3.
Target molecules accumulate directly within larval biomass
4.
Biomass is harvested and processed into high-volume biologic outputs
Unlike sterile cell culture or petrochemical synthesis, the platform is designed for continuous biological production at industrial scale.
Reliability Through Automation
FlyPharma’s platform couples genetic engineering with automated production systems to ensure consistent, high-volume output.
The platform is designed to deliver consistent output at industrial scale:
Automated rearing and environmental control systems reduce variability
Standardised process architecture enables repeatable scale-up
Integrated sensor networks monitor performance in real time
Continuous data feedback drives yield optimisation across production cycle
This closed-loop system transforms biological production into an engineered manufacturing process — delivering dependable supply at industrial scale.
Feed-Grade Economics, Industrial Volumes
Traditional biologics depend on sterile cell culture, high-cost media, or petrochemical synthesis.
These cost structures restrict biologics to niche or high-margin applications.
FlyPharma embeds molecular expression directly within a biological production host and automates the system end-to-end.
- Reduced capital intensity
- Low-cost biological inputs
- Short biological production cycles
- Designed for high-volume deployment
Biologics move from specialty input to scalable baseline component.
Engineered for Scale
Scalability is designed into the platform from first principles.
FlyPharma’s systems feature:
Fully automated rearing, harvesting, and processing
Short, predictable growth cycles enabling high throughput
Modular facility design that can be replicated rapidly
Distributed deployment without reliance on complex upstream infrastructure
This enables capacity to be added by replication rather than reinvention.
Platform Defensibility
FlyPharma is building a vertically integrated biologics production architecture — not a single product.
The same underlying expression system can produce multiple classes of bioactive compounds, including immune-active proteins and natural pigments. New products are layered onto an established production platform rather than built from scratch.
Defensibility is driven by integration across:
- Exclusive GM strain licensing and genetic engineering capabilities
- Coupled automation and production system design
- Proprietary insect-scale process engineering
- Data-driven yield optimisation across successive production cycles
Over time, advantages compound across genetics, automation, and process control.
This compounding advantage establishes a durable barrier to replication and a scalable foundation for future biologic products.
Partner With FlyPharma
FlyPharma engages selectively.
FlyPharma partners selectively with integrated producers, feed manufacturers, and strategic investors seeking to deploy next-generation biologics production at industrial scale.
We engage with organisations aligned on long-term commercial deployment and platform expansion.
If you are interested in exploring partnership or investment opportunities, we welcome the conversation.